Pediatric Optic Pathway Gliomas: A Report From Northern Greece.
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
16
03
2023
accepted:
28
07
2023
medline:
30
10
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
ppublish
Résumé
Optic pathway gliomas (OPGs) are the most common pediatric optic nerve tumors. Their behavior ranges between rapid growth, stability, or spontaneous regression. Τhey are characterized by low mortality albeit with significant morbidity. We present the characteristics, management, and outcome of 23 OPG patients (16 females, median age: 4.8 y) managed in a Pediatric Oncology Department in Northern Greece over a 25-year period. Overall, 57% had a background of neurofibromatosis type 1. Diagnosis was based on imaging (10 patients) or biopsy (13 patients). Presenting symptoms were mostly visual impairment/squint (52%). Proptosis/exophthalmos, raised intracranial pressure, and headache were also noted. In 2 occasions, it was detected with surveillance magnetic resonance imaging in the context of neurofibromatosis type 1. Eight patients had unilateral and 2 bilateral optic nerve tumors (Modified Dodge Classification, stage 1a/1b), 3 had chiasmatic (stage 2a/b), and 10 had multiple tumors (stage 3/4). Predominant histology was pilocytic astrocytoma (77%). Management included: observation (4), chemotherapy only (9), surgery only (3), or various combinations (7). Chemotherapy regimens included vincristine and carboplatin, vinblastine, or bevacizumab with irinotecan. Most patients demonstrated a slow disease course with complete response/partial response to chemotherapy and/or surgery, whereas 39% presented ≥1 recurrences. After a median follow-up of 8.5 years (range to 19 y), 20 patients (87%) are still alive with stable disease, in partial/complete remission, or on treatment.
Identifiants
pubmed: 37696004
doi: 10.1097/MPH.0000000000002753
pii: 00043426-202311000-00003
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445-451Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(suppl 5):v1–v100.
Fangusaro J, Onar-Thomas A, Poussaint TY, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium Study. Neuro Oncol. 2021;23:1777–1788.
Fried I, Tabori U, Tihan T, et al. Optic pathway gliomas: a review. CNS Oncol. 2013;2:143–159.
Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994;38:427–452.
Czyzyk E, Jóźwiak S, Roszkowski M, et al. Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol. 2003;18:471–478.
Listernick R, Darling C, Greenwald M, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr. 1995;127:718–722.
Packer RJ, Bilaniuk LT, Cohen BH, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis. 1988;1:212–222.
Beres SJ, Avery RA. Optic pathway gliomas secondary to neurofibromatosis type 1. Semin Pediatr Neurol. 2017;24:92–99.
Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018;33:73–81.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231–1251.
Huang M, Patel J, Patel BC. Optic nerve glioma [Updated 2022 May 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Rasool N, Odel JG, Kazim M. Optic pathway glioma of childhood. Curr Opin Ophthalmol. 2017;28:289–295.
Wan MJ, Ullrich NJ, Manley PE, et al. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. J Neurooncol. 2016;129:173–178.
Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8:30.
Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol. 2008;81:761–766.
Nicolin G, Parkin P, Mabbott D, et al. Natural history and outcome of optic pathway gliomas in children: pediatric optic pathway gliomas. Pediatr Blood Cancer. 2009;53:1231–1237.
El Beltagy MA, Reda M, Enayet A, et al. Treatment and outcome in 65 children with optic pathway gliomas. World Neurosurg. 2016;89:525–534.
Louis D, Cavenee WK. Neoplasms of the central nervous system DeVita V, Hellman S, Rosenberg S. Cancer: Principles and Practice of Oncology, 6th Edition. Lippincott Williams & Wilkins; 2001:2091–2160.
Gnekow AK, Falkenstein F, von Hornstein S, et al. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol. 2012;14:1265–1284.
Suharwardy J, Elston J. The clinical presentation of children with tumours affecting the anterior visual pathways. Eye. 1997;11:838–844.
Doganis D, Pourtsidis A, Tsakiris K, et al. Optic pathway glioma in children: 10 years of experience in a single institution. Pediatr Hematol Oncol. 2016;33:102–108.
Kokkinou E, Roka K, Alexopoulos A, et al. Development of a multidisciplinary clinic of neurofibromatosis type 1 and other neurocutaneous disorders in Greece. A 3-year experience. Postgrad Med. 2019;131:445–452.
Cassina M, Frizziero L, Opocher E, et al. Optic pathway glioma in type 1 neurofibromatosis: review of its pathogenesis, diagnostic assessment, and treatment recommendations. Cancers. 2019;11:1790.
Hill CS, Khan M, Phipps K, et al. Neurosurgical experience of managing optic pathway gliomas. Childs Nerv Syst. 2021;37:1917–1929.
Reis GF, Bloomer MM, Perry A, et al. Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system. Mod Pathol. 2013;26:1279–1287.
Jahraus CD, Tarbell NJ. Optic pathway gliomas. Pediatr Blood Cancer. 2006;46:586–596.
Pruzan NL, de Alba Campomanes A, Gorovoy IR, et al. Spontaneous regression of a massive sporadic chiasmal optic pathway glioma. J Child Neurol. 2015;30:1196–1198.
Thomas RP, Gibbs IC, Xu LW, et al. Treatment options for optic pathway gliomas. Curr Treat Options Neurol. 2015;17:2.
Zizka J, Eliás P, Jakubec J. Spontaneous regression of low-grade astrocytomas: an underrecognized condition? Eur Radiol. 2001;11:2638–2640.
Jenkin D, Angyalfi S, Becker L, et al. Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys. 1993;25:215–225.
Combs SE, Schulz-Ertner D, Moschos D, et al. Fractionated stereotactic radiotherapy of optic pathway gliomas: tolerance and long-term outcome. Int J Radiat Oncol Biol Phys. 2005;62:814–819.
Raikar SS, Halloran DR, Elliot M, et al. Outcomes of pediatric low-grade gliomas treated with radiation therapy: a single-institution study. J Pediatr Hematol Oncol. 2014;36:e366–e370.
Kortmann RD, Timmermann B, Taylor RE, et al. Current and future strategies in radiotherapy of childhood low-grade glioma of the brain: part II: treatment-related late toxicity. Strahlenther Onkol. 2003;179:585–597.
Greenberger BA, Pulsifer MB, Ebb DH, et al. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys. 2014;89:1060–1068.
Lassaletta A, Scheinemann K, Zelcer SM, et al. Phase II weekly vinblastine for chemotherapy-naïve children with progressive low-grade glioma: a Canadian Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2016;34:3537–3543.
Gururangan S, Fisher MJ, Allen JC, et al. Temozolomide in children with progressive low-grade glioma. Neuro Oncol. 2007;9:161–168.
Cardellicchio S, Bacci G, Farina S, et al. Low-dose cisplatin-etoposide regimen for patients with optic pathway glioma: a report of four cases and literature review. Neuropediatrics. 2013;45:042–049.
Yamasaki F, Takano M, Yonezawa U, et al. Bevacizumab for optic pathway glioma with worsening visual field in absence of imaging progression: 2 case reports and literature review. Childs Nerv Syst. 2020;36:635–639.
D’Angelo F, Lasorella A. Inhibition of ERK/MAPK signaling as potential therapy to prevent optic pathway glioma in infants with neurofibromatosis type 1. Dev Cell. 2021;56:2785–2786.
Galvin R, Watson AL, Largaespada DA, et al. Neurofibromatosis in the era of precision medicine: development of MEK inhibitors and recent successes with selumetinib. Curr Oncol Rep. 2021;23:45.
Green K, Panagopoulou P, D’Arco F, et al. A nationwide evaluation of bevacizumab-based treatments in pediatric low-grade glioma in the UK: safety, efficacy, visual morbidity, and outcomes. Neuro Oncol. 2023;25:774–785.
Greuter L, Guzman R, Soleman J. Pediatric and adult low-grade gliomas: where do the differences lie? Children. 2021;8:1075.
Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35:2370–2377.
Walker DA, Aquilina K, Spoudeas H, et al. A new era for optic pathway glioma: a developmental brain tumor with life-long health consequences. Front Pediatr. 2023;11:1038937.
Milde T, Rodriguez FJ, Barnholtz-Sloan JS, et al. Reimagining pilocytic astrocytomas in the context of pediatric low-grade gliomas. Neuro Oncol. 2021;23:1634–1646.
Aihara Y, Chiba K, Eguchi S, et al. Pediatric optic pathway/hypothalamic glioma. Neurol Med Chir (Tokyo). 2018;58:1–9.
Opocher E, Kremer LCM, Da Dalt L, et al. Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer. 2006;42:1807–1816.
Hoffman HJ, Humphreys RP, Drake JM, et al. Optic pathway/hypothaiamic gliomas: a dilemma in management. Pediatr Neurosurg. 1993;19:186–195.
DAY101 vs. standard of care chemotherapy in pediatric patients with low-grade glioma requiring first-line systemic therapy (LOGGIC/FIREFLY-2); 2022. Accessed July 24, 2023. https://clinicaltrials.gov/ct2/show/NCT05566795#wrapper